MiNK Therapeutics, Inc. announced on June 2, 2025, that it has been awarded a grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This grant will support the development of MiNK’s allo-iNKT cell therapy platform for the prevention and treatment of graft-versus-host disease (GvHD) following hematopoietic stem cell transplantation (HSCT).
The grant involves a collaboration with the University of Wisconsin, leveraging their expertise in transplant immunology. CEO Jennifer Buell, PhD, stated that this non-dilutive funding underscores the growing recognition of iNKT cells in immune regulation and accelerates development in an area of high unmet medical need.
GvHD is a severe immune complication after allogeneic HSCT, affecting nearly 50% of patients. iNKT cells are considered uniquely suited for this setting due to their ability to regulate immune responses, promote tissue repair, and suppress inflammatory pathways without requiring lymphodepletion or HLA matching.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.